ENGN
enGene Holdings Inc. Common Stock
NASDAQ: ENGN · HEALTHCARE · BIOTECHNOLOGY
$7.27
+3.27% today
Updated 2026-04-30
Market cap
$535.25M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.25
Dividend yield
—
52W range
$3 – $12
Volume
0.4M
enGene Holdings Inc. Common Stock (ENGN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | — | — | — | $175000.00 | $323000.00 | $509000.00 |
| Gross profit | — | — | — | $-175000.00 | $-323000.00 | $-509000.00 |
| Gross margin | — | — | — | — | — | — |
| R&D | $10.61M | $12.46M | $15.47M | $16.46M | $38.31M | $94.48M |
| SG&A | $3.24M | $3.15M | $3.26M | $8.47M | $23.98M | $28.68M |
| Operating income | $-13.85M | $-15.87M | $-19.43M | $-26.06M | $-62.30M | $-123.17M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-12.90M | $-18.14M | $-22.78M | $-94.77M | $-52.04M | $-113.80M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-13.16M | $-18.42M | $-23.02M | $-94.95M | $-52.36M | $-114.31M |
| Interest expense | $3.70M | $5.02M | $1.42M | $4.95M | $2.80M | $2.99M |
| Income tax | $4.33M | $4.90M | $22000.00 | $17000.00 | $-19000.00 | — |
| Effective tax rate | -40.4% | -26.4% | -0.1% | -0.0% | 0.0% | 0.0% |
| Net income | $-15.07M | $-23.44M | $-24.46M | $-99.92M | $-55.14M | $-117.30M |
| Net income growth (YoY) | — | -55.6% | -4.4% | -308.5% | +44.8% | -112.7% |
| Profit margin | — | — | — | — | — | — |